Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation
Head & Neck2020Vol. 42(12), pp. 3497–3505
Citations Over TimeTop 10% of 2020 papers
Derek K. Smith, Anthony J. Cmelak, K.J. Niermann, Michael K. Ghiam, Diane Lou, Jill Gilbert, Michael K. Gibson, Deborah K. Hawkins, Barbara A. Murphy
Abstract
Prophylactic use of gabapentin during chemoradiation for HNC patients resulted in a decrease in pain, neurosensory symptoms, and general systemic symptoms.
Related Papers
- Assessment of Oral Mucositis among Patients Undergoing Radiotherapy for Head and Neck Cancer: An Audit.(2020)
- → The relationship between oral health and radiation-induced mucositis among patients with head and neck cancer(2018)1 cited
- [The timing of the appearance of oral mucositis induced by concurrent chemoradiotherapy with S-1 for head and neck cancer].(2014)
- Effect of ice compress before radiotherapy on the symptoms of oral mucositis in patients with nasoplaryngeal cancer(2011)
- → EVALUATION OF LOW-INTENSITY LASER IN THE PREVENTION AND TREATMENT OF ORAL MUCOSITIS IN PATIENTS WITH HEAD AND NECK CANCER(2019)